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Abstract: Neurodegenerative diseases include a variety of pathologies such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and so forth,
which share many common characteristics such as oxidative stress, glycation, abnormal protein
deposition, inflammation, and progressive neuronal loss. The last century has witnessed significant
research to identify mechanisms and risk factors contributing to the complex etiopathogenesis of
neurodegenerative diseases, such as genetic, vascular/metabolic, and lifestyle-related factors, which
often co-occur and interact with each other. Apart from several environmental or genetic factors,
in recent years, much evidence hints that impairment in redox homeostasis is a common mechanism
in different neurological diseases. However, from a pharmacological perspective, oxidative stress is a
difficult target, and antioxidants, the only strategy used so far, have been ineffective or even provoked
side effects. In this review, we report an analysis of the recent literature on the role of oxidative stress
in Alzheimer’s and Parkinson’s diseases as well as in amyotrophic lateral sclerosis, retinal ganglion
cells, and ataxia. Moreover, the contribution of stem cells has been widely explored, looking at their
potential in neuronal differentiation and reporting findings on their application in fighting oxidative
stress in different neurodegenerative diseases. In particular, the exposure to mesenchymal stem cells
or their secretome can be considered as a promising therapeutic strategy to enhance antioxidant
capacity and neurotrophin expression while inhibiting pro-inflammatory cytokine secretion, which
are common aspects of neurodegenerative pathologies. Further studies are needed to identify a
tailored approach for each neurodegenerative disease in order to design more effective stem cell
therapeutic strategies to prevent a broad range of neurodegenerative disorders.
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1. Oxidative Stress and Neurodegenerative Diseases
Neurodegenerative diseases are a heterogeneous class of disorders characterized by a slow and
chronic loss of different neuronal populations in the central nervous system (CNS). Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and
spinocerebellar ataxia (SCA) are the most common neurodegenerative diseases [1]. They are a primary
public health problem, affecting tens of millions of people worldwide [2]. Although their complex and
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multifactorial etiology has not been fully elucidated, increasing evidence suggests a causative role of
oxidative stress in the onset and development of these disorders [3–6].
Oxidative stress, produced by an imbalance between reactive oxygen species (ROS) and the
endogenous antioxidant defense system [7], plays a key role in neurodegeneration as the brain is
characterized by an elevated oxygen consumption, high levels of iron and copper, involved in ROS
production, elevated content of polyunsaturated fatty acids, and low antioxidant defenses [1,8].
A schematic representation of causes and consequences of oxidative stress is shown in Figure 1. ROS
can be produced by the Fenton and Haber–Weiss reactions, in which redox-active metals interact with
oxygen species, or by the reactions catalyzed by NADPH oxidases or nitric oxide synthase (NOS).
The most investigated ROS are hydrogen peroxide (H2O2), superoxide (O2•−), and hydroxyl radical
(•OH). ROS are principally generated in the mitochondria, as they are the largest intracellular oxygen
consumer during electron transfer in mitochondrial respiratory chain by the interaction between
the leaking electrons and molecular oxygen [9]. Oxidative stress can also be induced by reactive
nitrogen species (RNS) [10]. RNS are produced by the fast reaction of O2•− with nitric oxide (NO),
resulting in the generation of peroxynitrite (ONOO−) that can trigger DNA fragmentation and lipid
peroxidation [11,12]. Three different isoforms of NOSs, namely endothelial (eNOS), neuronal (nNOS),
and inducible (iNOS), generate NO. It has also been observed that NO inhibits complexes I and IV of
the mitochondrial electron transport chain, inducing ROS generation [4].
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Cells respond to oxidative stress by inducing antioxidant enzymes that can neutralize ROS
counteracting cell damage [13,14]. In particular, nuclear factor erythroid 2-related factor 2 (Nrf2)
enhances the expression of these antioxidant enzymes thanks to its binding to a specific sequence
in the promoter region of these genes called antioxidant response element (ARE) [15,16]. In normal
physiological condition, Nrf2 is sequestered in the cytoplasm by Kelch-Like ECH-Associated Protein 1
(Keap1) that promotes ubiquitination and degradation of Nrf2 in the proteasome. Nevertheless, when
ROS or electrophiles modify the nucleophilic cysteine sulfhydryl groups on Keap1, Nrf2 is released and
it moves to the nucleus [17]. Furthermore, Nrf2 also exerts anti-inflammatory activity and modulates
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both biogenesis and mitochondrial function [18–20]. On these bases, Nrf2 is considered an interesting
therapeutic target in counteracting neurodegeneration [21,22].
In the following paragraphs, we describe the impact of oxidative stress in different
neurodegenerative diseases.
1.1. Alzheimer’s Disease
Alzheimer’s disease (AD) is the main cause of dementia and affects about 5.7 million Americans
and over 30 million people worldwide [23]. It is characterized by the degeneration and irreversible
loss of neurons and synapses in the brain impairing memory, personality, and cognitive functions.
Despite the several hypotheses explored to explain the origin of AD, the most accepted ones are
the extracellular deposition of Aβ protein, a 40–42-amino acid peptide generated by proteolytic
cleavages of the amyloid-protein precursor (APP), and intraneuronal neurofibrillary tangles (NFTs)
of hyperphosphorylated tau protein [24,25]. Another recognized hallmark of AD is oxidative stress
that, together with low levels of antioxidants and antioxidant enzymes, has been reported in the
brains of AD patients [26–29]. Oxidative stress, Aβ proteins, and NFTs are involved in a complicated
relationship: it has been suggested that oxidative stress induces Aβ aggregation and facilitates the
phosphorylation and polymerization of tau, and, in turn, protein deposition increases oxidative stress,
creating a vicious cycle [29].
Different lines of evidence suggest that Aβ induces oxidative stress. In particular, Aβ1–42 inserts
as oligomers into the bilayer and serves as a source of ROS inducing oxidative stress and initiating
lipid peroxidation [30]. Aβ is mainly accumulated in the extracellular regions but in lower amount is
also found in neurons [31]. Aβ in mitochondria may impair mitochondrial respiration, increasing ROS
generation, reducing ATP synthesis, and contributing to an altered calcium homeostasis [28,29]. High
level of mitochondrial ROS triggers mitochondrial DNA mutations that, in fact, are increased in AD
patients [29]. Moreover, Aβ amyloid is able to directly initiate ROS production by the activation of
NADPH oxidase [32]. Consequently, ROS overproduction triggered by Aβ proteins can alter cellular
signaling pathways causing tau hyperphosphorylation via the activation of p38 mitogen activated
protein kinases [1].
It has been evidenced a strict relation between tau pathology and oxidative stress. Oxidative stress
may promote hyperphosphorylation and polymerization of tau through the oxidation of fatty acids that
are elevated in AD and have been shown to increase tau polymerization [33]. It has been observed that
tau phosphorylation can be increased by p38 MAPK, that, in turn, is activated by oxidative stress [34].
On the other hand, the overexpression of tau protein increases cell vulnerability to oxidative stress,
and this has been related to the depletion of peroxisomes [35].
Oxidative stress can also be promoted by protein glycation in AD [36]. Glycation is an endogenous
process, triggered by high levels of glucose or by reactive endogenous aldehydes such as methylglyoxal
or glyoxal, leading to the generation of a group of species known as advanced glycation end products
(AGEs). Remarkably, high AGE levels have been detected in the brains of AD patients and glycosylation
increased Aβ and NFTs proteolytic resistance [36,37].
Another critical ROS source in AD brain is activated microglia. Within the CNS, microglia are
considered as the resident macrophages of the brain [38]. They rapidly respond to neuroinflammation
and damage interacting with astrocytes and neurons, assuming phagocytic phenotypes and releasing
pro-inflammatory cytokines, nitric oxide (NO), and ROS [39,40]. Microglia participate in Aβ
clearance [41], and, from this point of view, they can be both beneficial and deleterious: they
counteract Aβ deposition, but high levels of Aβ trigger a prolonged inflammatory condition that leads
to an overproduction of inflammatory mediators. Moreover, neuroinflammation causes an increase in
NO synthesis by microglia and astrocytes. High level of NO, in the presence of ROS, generates ONOO¯
and other reactive nitrogen species that are crucial contributors to oxidative stress in AD [42].
Different studies have suggested a relation between oxidative stress and glutamate excitotoxicity
in the neurodegenerative process of AD [43]. Glutamate is a neurotransmitter that has a critical role
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in learning and in the formation of memory through long-term potentiation (LTP) [44]. However,
a condition called glutamate excitotoxicity can occur when extracellular glutamate reaches high
concentrations leading to cell death caused by the excessive activation of the n-methyl-d-aspartate
receptor [45]. The impairment of these signaling pathways can trigger synaptic dysfunction, apoptosis,
and activation of the calcium-dependent pathway of calpain [46,47]. Mitochondrial dysfunction has
been indicated as one of the primary events in glutamate excitotoxicity [48]. Oxidative stress triggered
by mitochondrial dysfunction can damage neurons promoting the release of glutamate. Elevated
levels of glutamate in the synaptic cleft activate the receptors on adjacent neurons, and this causes
an excessive and sustained rise in free Ca2+ within them and therefore promoting a vicious circle of
neuronal damage [49].
In conclusion, oxidative stress has a fundamental role in AD and affects different molecular
pathways involved in AD brain cells (Figure 2). At the moment, what should be better understood
is whether oxidative stress plays a causative role in the onset of AD or is only a byproduct of other
AD mechanisms.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 29 
 
apoptosis, and activation of the calcium-dependent pathway of calpain [46,47]. Mitochondrial 
dysfunction has been indicated as one of the primary events in glutamate excitotoxicity [48]. 
Oxidative stress triggered by mitochondrial dysfunction can damage neurons promoting the release 
of glutamate. Elevated levels of glutamate in the synaptic cleft activate the receptors on adjacent 
neurons, and this causes an excessive and sustained rise in free Ca2+ within them and therefore 
promoting a vicious circle of neuronal damage [49]. 
In conclusion, oxidative stress has a fundamental role in AD and affects different molecular 
pathways involved in AD brain cells (Figure 2). At the moment, what should be better understood is 
whether oxidative stress plays a causative role in the onset of AD or is only a byproduct of other AD 
mechanisms. 
 
Figure 2. Schematic representation of ROS sources and their molecular targets in AD. Image created 
with BioRender.com. 
1.2. Parkinson’s Disease 
PD is the most common neurodegenerative disease after AD and affects 1–2% of the population 
over 65 and this rate increases to 4% in individuals above 85 years of age [50]. It is characterized by 
dopaminergic neuron loss in the substantia nigra pars compacta [51] and decreased dopamine (DA) 
levels in the nigrostriatal DA pathway in the brain [52]. The decrease in DA is associated with several 
sensory and motor impairments, in particular tremor, rigidity, and akinesia [53]. One distinctive 
characteristic of PD is the abnormal accumulation of Lewy bodies and Lewy neurites within neurons 
[54]. Insoluble α-synuclein fibrils are the principal constituent of both Lewy bodies and Lewy neurites 
[55]. 
Increasing evidence suggests that oxidative stress plays a major role in PD [4,56]. Even if the 
exact molecular mechanism causing dopaminergic cell death remains elusive, many studies observed 
that the substantia nigra pars compacta of PD patients is characterized by highly oxidized lipids, 
proteins, and DNA, together with low levels of glutathione [42]., Notably, in contrast to other regions 
of the brain, the substantia nigra is highly subjected to ROS attack because neurons are exposed to 
additional oxidative stress due to their dopamine metabolism, low content of antioxidants, and high 
iron concentration [57]. Dopamine is oxidized by monoamine oxidases A and B with the production 
of hydrogen peroxide. In addition, dopamine is subjected to auto-oxidation with the production of 
Figure 2. Schematic representation of ROS sources and their molecular targets in AD. Image created
with BioRender.com.
1.2. Parkinson’s Disease
PD is the most common neurodegenerative disease after AD and affects 1–2% of the population
over 65 and this rate increases to 4% in individuals above 85 years of age [50]. It is characterized
by dopaminergic neuron loss in the substantia nigra pars compacta [51] and decreased dopamine
(DA) levels in the nigrostriatal DA pathway in the brain [52]. The decrease in DA is associated
with several sensory and motor impairments, in particular tremor, rigidity, and akinesia [53]. One
distinctive characteristic of PD is the abnor al accumulation of Lewy bodies and Lewy neurites within
neurons [54]. Insoluble α-synuclein fibrils are the principal constituent of both Lewy bodies and Lewy
neurites [55].
Increasing evidence suggests that oxidative stress plays a ajor role in PD [4,56]. Even if the
exact olecular echanism causing dopa inergic cell death re ains elusive, any studies observed
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that the substantia nigra pars compacta of PD patients is characterized by highly oxidized lipids,
proteins, and DNA, together with low levels of glutathione [42]., Notably, in contrast to other regions
of the brain, the substantia nigra is highly subjected to ROS attack because neurons are exposed to
additional oxidative stress due to their dopamine metabolism, low content of antioxidants, and high
iron concentration [57]. Dopamine is oxidized by monoamine oxidases A and B with the production
of hydrogen peroxide. In addition, dopamine is subjected to auto-oxidation with the production of
quinones, peroxide, and oxy-radicals [58]. In healthy and young individuals, the DA transporter (DAT)
protects dopaminergic neurons against oxidized DA [57]. Oxidized DA is taken up by DAT into the
nerve terminal, where vesicular monoamine transporter 2 (VMAT2) repackage DA in the synaptic
vesicles. Unfortunately, a significant age-related decline in the DAT has been observed, typically
around 5.6–6.1% per decade, which has been associated to dopaminergic neuron loss in the substantia
nigra and increase of oxidative stress [59]. DA oxidation to o-quinones is also an essential event
required for neuromelanin synthesis [60]. In healthy individuals, neuromelanin acts as a protective
factor in the substantia nigra; however, in PD patients, the modification of the composition and
density of neuromelanin is suggested to increase ROS production and iron concentration [61,62]. It has
been observed that α-synuclein accumulates on neuromelanin, leading to a significant reduction in
neuromelanin density within substantia nigra of dopaminergic neurons [4], altering the neuroprotective
function of neuromelanin in PD. In fact, neuromelanin has a fundamental role in blocking reactive iron,
forming stable complex with it, then preventing iron toxicity [60]. Different studies have demonstrated
higher levels of iron in the brain of PD patients [63,64], which has also been associated to the impaired
iron transport into the mitochondria in dopaminergic neurons in PD patients [65,66].
Another important oxidative stress production site in PD is the mitochondria as suggested by the
decrease of Complex I activity in the respiratory chain in the substantia nigra in PD [67]. As underlined
above, together with an increase of oxidative stress in postmortem PD substantia nigra, a reduction in
the levels of GSH has been observed [68–70]. GSH is a fundamental endogenous antioxidant and a
decrease in its concentration inevitably leads to an enhanced ROS production.
Moreover, extensive inflammation has been reported in PD, as demonstrated by high levels of
pro-inflammatory cytokines such as IL-1b, TNF-a, IL-2, and IL-6, measured in PD patients, in the
post-mortem brain, and in serum and cerebrospinal fluid in vivo [71]. Since inflammation is associated
to a huge release of ROS [72], and as PD patients are exposed to a long-term strong chronic inflammation
in the brain, oxidative stress can be exacerbated in these patients [72].
Summarizing, similar to AD, oxidative stress seems to have both a causal role and being a
consequence of different pathological conditions in PD (Figure 3). In this context, the auto-oxidation of
dopamine is an additional element that contribute to oxidative stress.
1.3. Amyotrophic Lateral Sclerosis
Among the various neurodegenerative diseases, ALS is the most common neuromuscular disorder
that leads to lethal respiratory paralysis within 3–5 years of diagnosis [73]. Usually it occurs after
50 years of age, has an incidence of around five people per 100,000 worldwide, and is more frequent in
men [74]. ALS can be classified as either sporadic or familial form, with the majority of cases among the
population being sporadic. The term sporadic refers to ALS that has no clear genetic relationship and
occurs without a family history of ALS. On the other hand, 10% of cases can be familial and triggered
by mutations in some genes, such as SOD1, TDP43, C9orf72, and FUS [73].
The dominant pathological characteristic of ALS is the occurrence of inclusions in the cytoplasm
or aggregates into motor neurons and nearby oligodendrocytes. The principal aggregates present
in patients suffering ALS are ubiquitinated aggregates and can be either Lewy body-like hyaline
inclusions or skein-like inclusions [75]. Ubiquitinated aggregates observed in ALS can induce ROS
generation both in the cytosol and in mitochondria [76–78].
Int. J. Mol. Sci. 2020, 21, 3299 6 of 28
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 29 
 
quinones, peroxide, and oxy-radicals [58]. In healthy and young individuals, the DA transporter 
(DAT) protects dopaminergic neurons against oxidized DA [57]. Oxidized DA is taken up by DAT 
into the nerve terminal, where vesicular monoamine transporter 2 (VMAT2) repackage DA in the 
synaptic vesicles. Unfortunately, a significant age-related decline in the DAT has been observed, 
typically around 5.6–6.1% per decade, which has been associated to dopaminergic neuron loss in the 
substantia nigra and increase of oxidative stress [59]. DA oxidation to o-quinones is also an essential 
event required for neuromelanin synthesis [60]. In healthy individuals, neuromelanin acts as a 
protective factor in the substantia nigra; however, in PD patients, the modification of the composition 
and density of neuromelanin is suggested to increase ROS production and iron concentration [61,62]. 
It has been observed that α-synuclein accumulates on neuromelanin, leading to a significant 
reduction in neuromelanin density within substantia nigra of dopaminergic neurons [4], altering the 
neuroprotective function of neuromelanin in PD. In fact, neuromelanin has a fundamental role in 
blocking reactive iron, forming stable complex with it, then preventing iron toxicity [60]. Different 
studies have demonstrated higher levels of iron in the brain of PD patients [63,64], which has also 
been associated to the impaired iron transport into the mitochondria in dopaminergic neurons in PD 
patients [65,66].  
Another important oxidative stress production site in PD is the mitochondria as suggested by 
the decrease of Complex I activity in the respiratory chain in the substantia nigra in PD [67]. As 
underlined above, together with an increase of oxidative stress in postmortem PD substantia nigra, a 
reduction in the levels of GSH has been observed [68–70]. GSH is a fundamental endogenous 
antioxidant and a decrease in its concentration inevitably leads to an enhanced ROS production.  
Moreover, extensive inflammation has been reported in PD, as demonstrated by high levels of 
pro-inflammatory cytokines such as IL-1b, TNF-a, IL-2, and IL-6, measured in PD patients, in the 
post-mortem brain, and in serum and cerebrospinal fluid in vivo [71]. Since inflammation is 
associated to a huge release of ROS [72], and as PD patients are exposed to a long-term strong chronic 
inflammation in the brain, oxidative stress can be exacerbated in these patients [72].  
Summarizing, similar to AD, oxidative stress seems to have both a causal role and being a 
consequence of different pathological conditions in PD (Figure 3). In this context, the auto-oxidation 
of dopamine is an additional element that contribute to oxidative stress. 
 
Figure 3. Schematic representation of ROS sources and their molecular targets in PD. Image created 
with BioRender.com. 
Figure 3. Schematic representation of ROS sources and their molecular targets in PD. Image created
with BioRender.com.
In turn, oxidative stress might alter protein structure, producing abnormal protein inclusions,
generating in this way a detrimental loop [79].
Different studies showed the involvement of several factors in ALS, such as neuroinflammation,
mitochondrial dysfunction, excitotoxicity, stress of the endoplasmic reticulum, and oxidative stress [80].
Increased levels of protein oxidation, nitration, and carbonylation, together with lipid peroxidation,
have been widely observed in familial and sporadic ALS patients and in different models of the
disease [81–83], indicating a crucial role of oxidative stress in the pathogenesis of ALS [84].
The impairment of the activity of mSOD1 and other ALS-linked proteins, such as mutant TDP-43,
increases ROS and triggers oxidative stress [85,86].
Excitotoxicity and oxidative stress are strictly related in ALS [87]. As previously underlined,
neuronal excitotoxicity is characterized by an elevation of cytosolic free calcium that, in turn, activates
calcium-dependent enzymes, such as proteases and enzymes including xanthine oxidase, phospholipase
A2, and NOS that can produce ROS and RNS [88]. Moreover, motor neurons are especially sensitive to
increases in cytosolic free calcium levels because, compared to other kinds of neurons, they are rather
poor in some proteins that bind calcium such as calbindin D-28k and parvalbumin [89].
Neurons persist throughout the existence of an organism and, for this reason, the preservation
of healthy mitochondria is crucial for the survival and function of neurons. It is thus not surprising
that mitochondrial dysfunction has been associated not only to AD and PD but also to ALS [90].
Indeed, damaged mitochondria are an early change observed in motor neurons of ALS patients [91,92].
This damage can be due to different factors including the interaction of proteins linked to familial and
sporadic ALS with mitochondria [93–95]. ALS associated mitochondrial dysfunction unavoidably
leads to the production of ROS and to oxidative stress.
In ALS, another cause of ROS production is inflammation, observed in both patients suffering ALS
and mSOD1 mice [87]. Indeed, a strong increase in pro-inflammatory markers such as interleukin-6
(IL-6), monocyte chemoattractant protein-1 (MCP-1), IL-8, and cyclooxygenase-2 (Cox-2) is present in
ALS [96–100]. It has also been evidenced that macrophages infiltrate ventral spinal roots, peripheral
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motor nerves and skeletal muscles in ALS mouse models [101,102]. Therefore, activated macrophages
might also contribute to ROS production via NADPH oxidases in axons and muscle in ALS [87].
Moreover, microgliosis is an important contributor to neurodegeneration as well as oxidative stress.
Indeed, in human spinal cord samples of ALS mouse model, high NOX2 expression was detected
in microglia [103]. The authors demonstrated that NOX inhibition with thioridazine significantly
decreased superoxide levels in the spinal cord and dampened the increase of microglia markers in
SOD1(G93A) mice, thus resulting in an immediate and temporary enhancement of motor performance.
Furthermore, diminishing ROS produced by microglia by treatment with another NOX inhibitor
apocynin or by elimination of NOX has been reported to extend survival in ALS mice, reviving the
proposal that ROS mediate ALS pathogenesis [104].
In conclusion, oxidative stress plays a fundamental role in ALS being both cause and consequence of
other impaired functions. ALS, indeed, is characterized by a complex network of molecular mechanisms
underpinning neurodegenerative processes, in which disturbances in redox homeostasis, as common
mechanism behind oxidative stress, inflammation, and excitotoxicity, play a fundamental role.
1.4. Oxidative Damage of Retinal Ganglion Cells
Retinal ganglion cells (RGCs) are neurons located near the inner retina surface, that receive
visual information from photoreceptors, allowing the connection between brain and visual world.
There are over a million RGCs in the eyes, classified according to different physiological, morphological,
and molecular criteria [105]. RGCs represent one of the central cell types damaged in many ocular
neurodegenerative diseases, characterized by oxidative stress, such as diabetic retinopathy [106,107],
glaucoma [108,109], and retinal ischemia-reperfusion injury [110,111]. It has been proved that oxidative
stress plays a pivotal role in the loss of RGCs in several eye diseases. Moreover, aging process
aggravates the injury in RGCs through several processes, such as DNA damage, oxidation of proteins,
apoptosis, cell death, etc. As previously reported, the Nrf2/Keap1/ARE signaling pathway is one of the
key protection mechanisms against oxidative stress and the inducers of this signaling pathway can
be considered as emerging target with a neuroprotective effect in RGCs [112–114]. Indeed, a recent
review discusses the effect of several Nrf2 inducers that protect RGCs from oxidative stress-induced
optic neuropathies by regulating Nrf2 signaling [115].
1.5. ROS and Ataxia
Ataxia is the cardinal symptom of genetic disorders or secondary lesions affecting the central
nervous system. It is characterized by the progressive and inevitable loss of muscle control, associated
with a difficulty in executing voluntary movements. There are many forms of ataxia, classified
according to the affected anatomical region, the triggering cause, the age of onset, and other features.
Friedrich’s Ataxia is probably the most common form of this type of neurological diseases. Friedreich
ataxia is a genetic disease caused by the deficiency of frataxin, a mitochondrial protein supposed to
work such as a metal chaperone and iron storage protein [116]. Frataxin-deficient cells were often
observed to be highly sensitive to oxidizing agents [117,118]. Some authors have proposed that such
sensitivity is associated to weakened biosynthesis of iron-sulfur centers. Thus, a vicious cycle would
be generated in which the insufficient formation of iron-sulfur clusters would enhance mitochondrial
free iron that, in turn, provokes ROS production through Fenton reaction. Thereafter, ROS would
further impair iron-sulfur clusters, driving to the formation of more free iron. However, looking at
the mitochondrial iron pools, no differences were observed between controls or Friedrick’s ataxia in
human lymphoblasts or fibroblasts [119]. Nevertheless, some authors have suggested that oxidative
stress could occur upstream (and not be the consequence) of iron-sulfur deficiency [116]. Undoubtedly,
frataxin deficiency is reported to affect cell physiology at several levels, such as oxidative stress
causing protein and DNA dysfunctions. Moreover, alterations in lipid metabolism have been observed
in several models of the disease [117]. Therefore, increased oxidative stress together with chronic
reduction of endogenous antioxidants causes neurodegeneration and affects cell survival. Indeed,
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it has been observed a significant increase in ROS and lipid peroxidation and a lower level of GSH in
cerebellar granule neurons [120,121]. Moreover, Armstrong et al. highlighted that any alteration in
the OXPHOS chain, caused by frataxin deficiency, could induce electron leakage and thus produce
ROS [122].
All these effects due to an increased ROS production linked to mitochondrial dysfunction, as well
as more significant oxidative damage have been shown likewise in other ataxia cell models [123–125].
2. Mesenchymal Stem Cells Potential in Neuronal Differentiation
To clarify the choice to focus our attention on mesenchymal stem cells application in
neurodegenerative diseases, a whole picture of different stem cells characteristics, with advantages
and drawbacks, is reported below. Stem cells can be categorized as embryonic stem cells (ESCs),
induced pluripotent stem cells (iPSCs), fetal stem cells (FSCs), perinatal stem cells (PSCs), and adult
stem cells (ASCs) [126]. ESCs are pluripotent stem cells isolated from the inner cell mass of blastocysts
before the stage of gastrulation [127,128]. They have advantages for self-renewal and differentiation
even if the formation of in vivo teratomas is a problematic point. An additional complication is to
find patient-matched ESCs. Moreover, there are many ethical concerns since the isolations of ESCs
implies the destruction or manipulation of human embryo [129]. Interestingly, the more recent use
of induced pluripotent stem cells (iPSCs) carries similar advantage and concerns, since iPSCs show
comparable pluripotency potential to ESCs, but, being created from adult somatic cells through
epigenetic reprogramming, ethical problems are avoided [130] and it also makes possible personalized
cell therapy. However, generation of pluripotency and some of the procedures of reprogramming itself
cause genomic instability affecting cell integrity. Moreover, the reprogramming factors (such as c-Myc)
are known to be proto-oncogenes [131].
Fetal stem cells (FSCs) are obtained from fetal tissues of the beginning of the second trimester, such
as amniotic fluid stem cells; therefore, they exhibit a lower stemness property than ESCs [132], even if
they are defined as broadly multipotent [133]. Fetal as well as perinatal stem cells are of high interest
since these cells can be easily isolated from discarded samples at the end of prenatal screening during
second trimester or as clinical waste material after birth. Interestingly, FSCs share characteristics with
both adult and embryonic stem cells, still maintaining high self-renewal, but without tumorigenic and
ethical concerns [134].
Finally, adult stem cells (ASCs), from both allogeneic and autologous sources, are multipotent
cells found in most adult tissues, even if in different amount, where they are responsible of tissue
regeneration [135]. However, the age of the donor is linked to progressive decline of stem cell
function [136].
Multipotent stem cells resident into the brain, neural stem cells (NSCs), are highly expandable
ex vivo, but the transplantation of developing NSCs into the adult brains implies numerous ethical,
scientific, and legislative hurdles [137]. Moreover, human neurogenesis drastically diminishes during
aging and, as a consequence, NSC and neural precursor cells proliferation and differentiation are
nearly undetectable [138] or they occur to a lesser extent and are restricted to defined areas, such as
circumventricular organs [139] and the dentate gyrus [140].
With the purpose of stem cell therapy application for replacing degenerated cells in
neurodegenerative disorders and NS lesions, mesenchymal stem cells (MSCs), adult stem cells
generated from the mesoderm and neuroectoderm [141], show an elevated differentiation plasticity.
These cells can be obtained from adult tissues, such as adipose tissue and bone marrow, but also from
fetal tissues, such as umbilical cord blood, among other tissues. These stem cells have remarkable
therapeutic properties and different advantages in respect to other adult stem cells such as NSCs.
For example, not only fetal but also adult mesenchymal stem cells derived from adipose tissue exhibit
triploblastic differentiation, thus pluripotency, both spontaneously and under media-specific induction,
without forming teratomas [142]. Moreover, MSCs migrate towards inflammatory areas due to the
expression of chemokine receptors [143], and, thanks to the immunomodulatory capacity, the use
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of MSCs might elude the side effects of the immunosuppressive treatment used with NSCs [144].
In addition, gestational tissues contain MSCs stem cells that inhibit or limit inflammatory responses
and promote anti-inflammatory pathway. Perinatal stem cells express and secrete an arsenal of
anti-inflammatory and pro-regenerative cytokines, involved in extracellular matrix remodeling and
angiogenesis including macrophage inhibitory protein and hepatocyte growth factor [145]. Thus, MSCs
isolated from fetal tissues may be considered a good alternative to adult MSCs for clinical applications,
thanks to the previously reported advantages and because, unlike adult stem cells, they have the
benefit of carrying fewer environmental induced mutations due to their early gestational derivation.
Nevertheless, when implanted in the injured region, beside differentiation and integration onto
the damaged tissue, therapeutic effect of MSCs could be due to different mechanisms: secretion of
neurotrophic factors [146], astroglial activation and neurogenesis induction [147], axon growth [148],
enhancement of synaptic and cortical interhemispheric connections [149], immunomodulatory and
anti-inflammatory properties [150], and decrease of apoptosis and oxidative stress [151]. Many
cells types secrete exosomes as key players in cell–cell communication: exosomes contain many
bioactive molecules and can regulate the expression of genes associated to neuronal development
and transcription factors [152]. Exosomes can be considered as a tool to improve the modification
of adult stem cells, namely endogenous NSCs, even eliminating the need for stem cell injection into
the brain [153]. Thus, administration of conditioned media derived from MSCs could contribute in
maintaining the increased paracrine factor gradient between the diseased organ and the stem cell niche
in order to speed up the process of recovery. Based on the principle of paracrine signaling mechanism,
the secretome of the MSCs is a rich source of the paracrine factors [154]. However, regarding the
capability of MSCs to differentiate into neuronal cells, many studies have been conducted, by using
several differentiation protocols, with contrasting results. Culture media with growth factors and
other substances promote the differentiation of MSCs in vitro towards various neuronal cell types
displaying differences in morphology and functions [155]. Indeed, various media have been used for
neurogenic differentiation. Table 1 shows the supplements most frequently used and the neuronal cell
types obtained after differentiation of MSCs.
Considering all these aspects, MSCs are simpler to use in the clinical practice, also compared
to ESCs, by the easy preparation and by immunologic and ethic privileges. Moreover, MSCs and
their secretome seem to be able to pass the blood–brain barrier, avoiding invasively intracerebral
transplantation [156]. For these reasons, US FDA approved their use in clinical treatment for many
disorders, including age-related diseases such as neurodegenerative disorders. Cell therapy has been
evidenced to alleviate symptoms or even to reverse disease progress in neurological disorders where
classical pharmacological treatments are no longer sufficient or are not available [157].
However, in their review, Peng et al. concluded that more data are needed to demonstrate the
efficacy of the MSC-based cellular therapies in the treatment of neurodegenerative disorders [158].
Moreover, the studies reviewed by Peng et al. [158] already suggested that MSCs induced endogenous
neuronal growth by a paracrine action, reduced free radicals levels, and regulated inflammation, thus
stimulating functional recovery.
The observation that MSC secretome possesses antioxidant properties has also been proved
in other contexts. In the injured liver, hypoxic conditioned media derived from adipose stem cells
provided protection against ROS-related toxicity by increasing the expression of antioxidant enzymes,
in part by releasing Nrf2 [159]. Bellei et al. [160] recently demonstrated that secreted molecules,
obtained from adipose tissue, ameliorated the ability to dampen oxidative stress through a rise on
intracellular antioxidant enzymes that improved cell proliferation in dermal and epidermal vitiligo
cells in vitro.
Based on these observations, in the following paragraphs, we report recent evidence on the role of
MSCs or their secretome in counteracting neurodegenerative disorders by modulating oxidative stress.
Tables 2 and 3 summarize the in vitro and in vivo studies reported below.
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3. Mesenchymal Stem Cells Contrast Neuronal Cell Damage Induced by Oxidative stress
Most of the literature suggests a beneficial effect of MSCs in neurodegeneration, demonstrating
a molecular mechanism that involves the regulation of oxidative stress in vitro. For example,
Baez-Jurado et al. [161] investigated the effect of conditioned medium (CM) of MSCs derived from
human adipose tissue (AD) in a model of human astrocytes (T98G cells) subjected to scratch injury.
Their findings demonstrated that CM-AD-MSC modulates mitochondrial dynamics and the respiratory
chain, downregulates calcium in the cytoplasm, and settles the cytokines IL-2, IL-6, IL-8, IL-10, GM-CSF,
and TNF-α. In parallel to these effects, a modulation of signaling pathways, such as AKT/pAKT and
ERK1/2/pERK, occurs, and it can be linked to the intracellular localization of neuroglobin, mediating
the protective effects of CM-AD-MSC through tuning of proteins implicated in survival pathways and
oxidative stress.
Mesenchymal stem cells, derived from the orbital adipose tissue, were demonstrated to possess
neuroectodermal differentiation and repair ability in a recent study by Mawrie et al. [162]. In fact,
also this particular type of MSCs abrogated neuronal cell damage induced by oxidative stress and
expressed several neurotrophic factors, suggesting that the use of the MSCs and their secreted factors
may represent a promising tool for neurological disease treatment.
The strategy to improve the antioxidant efficacy of MSC was explored in a recent paper by
Wen et al. [163]. They investigated the antioxidant effects of secretions from BMSCs pretreated with
berberin (BBR) on tert-butyl hydroperoxide (t-BHP)-damaged neurons, demonstrating that BBR can
enhance BMSC viability and the secretion of nerve growth factor (NGF) and brain-derived neurotrophic
factor (BDNF). These effects of conditioned medium (BBR-BMSC-CM) were related to a reduced ROS
production, and may be due to an activation of the antioxidant proteins Keap1, Nrf2, and HO-1, and
a decrease in the mitochondrial membrane potential. Thus, BBR-BMSC-CM ameliorated neuronal
synaptic function and neuronal apoptosis by decreasing levels of the apoptotic proteins Bax/Bcl-2,
cytochrome c, and cleaved caspase-3/caspase-3.
To induce neurotoxicity, Palomares et al. [164] used an in vitro model of ec23/brain-derived
neurotrophic factor (BDNF)-differentiated human SH-SY5Y neuron-like cells (SH-SY5Yd) exposed
to H2O2. The effect of conditioned medium from human AD-MSCs was neuroprotective; indeed,
stressed SH-SY5Y cells recovered normal axonal, electrophysiological features, and cell viability.
The antioxidant capacity of AD-MSC conditioned medium and the presence of growth factors, namely,
BDNF, glial cell line-derived neurotrophic factor, and transforming growth factor β1, are considered
the involved therapeutic factors. However, the addition of the antioxidant agent N-acetyl cysteine to
AD-MSC-CM eliminated its curative effect; this could be due to a strong reduction in ROS, in contrast
to the moderate decrease in ROS produced by AD-MSC-CM alone.
On the other hand, not all the studies suggest a positive effect of MSCs against neuron toxicity and
ROS modulation. Indeed, when rat organotypic hippocampal cultures were exposed to CM obtained
from MSCs isolated from rat bone marrow, cell toxicity in hippocampal cultures occurs. Furthermore,
MSC-CM worsens cell death induced by glucose and oxygen deprivation. This negative effect was due to
a marked glial cell activation after exposure of cultures to MSC-CM, as demonstrated by Horn et al. [165].
In fact, TNF-α and interleukin-6 levels were increased in the culture medium as well as ROS and
iNOS, hinting that MSC-secreted factors induce reactive species generation and neuroinflammation
in organotypic cultures of hippocampus. The involvement of microglial cells was also studied in
a recent paper of Cao et al. [166] reaching the opposite conclusions. Specifically, the human bone
marrow-derived mesenchymal stem cells (hBM-MSCs) significantly inhibited lipopolysaccharide (LPS)
activation of microglial cells. In particular, these data indicate an inhibitory effect of hBM-MSCs on
oxidative stress and pro-inflammatory mediators, involving the AMPK pathway in LPS-activated
microglial cells.
These results suggest that neuronal therapeutic effect of stem cells is due to not only the release
of essential neurotrophic factors, but also to the maintenance of an appropriate redox state that
preserves neuronal function. Moreover, appropriate cell culture conditions are necessary to maintain
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the properties of stem cells ex vivo for clinical applications taking into consideration the fundamental
role of the cellular redox status [7,167].
In conclusion, a fine regulation of brain inflammation, associated to the rescue of essential cellular
redox features in contrast to injury, makes CM-MSCs, more than MSCs, a promising protection tool for
astrocytes and neurons in brain pathologies.
3.1. Mesenchymal Stem Cells Modulate Redox State in Alzheimer’s Disease
Neuronal cells treated with Aβ are widely used as an AD model as the extracellular deposition of
Aβ protein plays a pivotal role in AD pathogenesis and progression. In a study by Lee et al. [168],
cultured hippocampal neurons, treated with Aβ, were exposed to human umbilical cord blood-derived
mesenchymal stem cells (hUCB-MSCs). hUCB-MSCs presence reduced apoptosis of hippocampal
neurons induced by Aβ. Moreover, the authors showed that markers of oxidative stress, glial activation,
and apoptosis levels declined in an acute AD mouse model. Interestingly, AD mice injected with
hUCB-MSCs displayed cognitive rescue with improved learning/memory function.
In a AβPP/PS1 mouse model of AD, intravenous infusion of hUCB-MSCs significantly improved
spatial learning and alleviated memory decline, as demonstrated by Yang [169]. hUCB-MSC treatment
increased glutathione (GSH) activity and ratio of GSH to oxidized glutathione as well as superoxide
dismutase activity, while decreased malondialdehyde activity and protein carbonyl levels, suggesting
that hUCB-MSC infusion alleviates oxidative stress in AβPP/PS1 mice. In addition, hUCB-MSC
infusion reduced β-secretase 1 and CTFβ, thus reducing Aβ deposition in mice.
Furthermore, the secretome of MSCs, namely extracellular vesicles (EVs) derived from human
Wharton’s jelly mesenchymal stem cells, is able to defend hippocampal neurons from oxidative stress
and to avoid synapse damage prompted by amyloid-β oligomers. Indeed, Bodart-Santos et al. [170]
recently demonstrated that hMSC-EVs were captured by hippocampal cells, and this uptake was
improved in the presence of Aβ oligomers in the medium. Interestingly, neuroprotection by hMSC-EVs
was related to the transfer of active antioxidant enzyme catalase contained in EVs.
The observation that MSC treatment has the potential to ameliorate Aβ pathology in AD model
mice, modulating oxidative stress through regulation of microglial functions, was recently confirmed by
Yokokawa et al. [171], both in vitro, by co-culturing the mouse microglial cell line MG6 with MSCs, and
in vivo, using an AD mice (APdE9) model. MSCs induced the switch of microglial phenotype from M1
to M2 and reduced secretion of proinflammatory cytokines. Moreover, MSC transplantation enhanced
microglia accumulation around Aβ deposits triggering microglial Aβ uptake and elimination. MSCs
injected into the tail vein ameliorated spatial memory through a lower Aβ deposition in the cortex
and hippocampus. To evaluate the redox state of the brain in vivo, they used electron paramagnetic
resonance imaging, and they clearly demonstrated that MSC transplantation inhibited oxidative stress
in this AD mice model.
All these findings suggest that the regulation of redox state both inside neurons, inducing
an increase of antioxidant enzyme level, and in the extracellular microenvironment, modulating
the microglia activation, could prevent the progression of AD. Further studies on tau AD models
are needed to confirm the redox state as a common key that is exploited by MSC to contrast this
neurodegenerative disease.
3.2. Antioxidant Effects of Mesenchymal Stem Cells in Parkinson’s Disease
Mesenchymal stem cells and mouse embryonic stem cells are capable of generating neuronal
precursors (NPs), which are a promising therapeutic strategy for neurological disorders due to their
capacity to differentiate into functional astrocytes, oligodendrocytes, and mature neurons. Edwards
Iii et al. [172] intravenously administered NPs in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) mouse model of PD. Previous research using intracerebral stem cell therapy for treatment of
PD has provided promising results; however, this method is very invasive and is often associated with
unacceptable side effects. These mice treated with NPs showed enhanced motor function and reduced
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neuroinflammatory response. It can be concluded that peripheral administration of stem cell-derived
NPs could be used as valid therapy to treat PD brain pathology through the restoration of damaged
motor function.
The mechanisms involved into the neuroprotective activity of MCSs were explored by using the
conditioned media obtained from rat adipose tissue-derived MSCs (rAD-MSCs) in vitro models of PD
neurodegeneration obtained exposing SH-SY5Y cells to pro-oxidizing agents such as hydrogen peroxide
or the dopaminergic selective toxin 6-hydroxydopamine (6-OHDA) [173]. When neuroblastoma
SH-SY5Y cells were exposed to CM of rAD-MSCs, cytotoxicity and ROS generation were reduced,
through the upregulation of the antioxidant enzyme sirtuin 3 (SIRT3).
Notably, fetal stem cells, such as naïve human chorial villi (hCVCs) and cells derived from
amniotic fluid (hAFCs), expressing some exclusive markers of neural stem/progenitor, such as nestin
and connexin 43, also secrete BDNF and vascular endothelial growth factor. hCVC and hAFC
populations are indeed composed of different cell lineages, including MSCs and cells with neural-like
phenotypes. Calzarossa et al. [174] demonstrated that CMs derived from both cell types increased
metabolic activity in a cell model of PD induced by 6-OHDA, but only hCVC-derived CM significantly
diminished apoptosis induced by neurotoxin. The choice to use naïve cells instead of selecting stem
cells population contained in chorial villi and amniotic fluid could be the reason for these contrasting
results. However, they concluded that naïve hCVCs and hAFCs may contrast cell-neuronal damage by
different mechanisms, and can be considered a promising stem cell therapy for neurodegenerative
diseases including PD.
Another study showed that conditioned medium, obtained from human menstrual blood-derived
endometrial stem cells (MenSCs-CM), and not the cells itself, alleviated the symptoms of PD [175].
Human neuroblastoma SH-SY5Y cells were exposed to neurotoxicant 1-methyl-4-phenylpyridinium
(MPP+) in order to obtain PD features. Then, pro-inflammation cytokines, oxidative stress,
mitochondrial membrane potential (∆Ψm), cell viability, and cell apoptosis were assessed. MenSCs-CM
demonstrated efficacy in contrasting MPP+ induced inflammation, ROS generation, ∆Ψm loss, and
decreased apoptosis and this protective effect could be related to various neuroprotective factors
contained in MenSCs-CM.
In conclusion, the complexity of the stem cell secretome, including neuroprotective, neurotrophic,
antiapoptotic, anti-inflammatory, and antioxidant molecules, can be considered the winning factors to
counteract PD.
3.3. Mesenchymal Stem Cells Counteract Oxidative Stress in Other Brain Disorders
Damages to ganglion cells are often associated to other diseases, such as diabetes. Ezquer et al. [176]
assessed that the intravitreal administration of adipose-derived MSCs avoided the loss of retinal
ganglion cells in diabetic mice. Indeed, MSC injection significantly slowed down retinal ganglion
cell loss. However, engrafted donor cells in the vitreous cavity did not differentiate into neural or
perivascular-like cells, but their effect was to induce higher intraocular levels of several neurotrophic
factors (basic fibroblast growth factor, nerve growth factor, and glial cell line-derived neurotrophic
factor) and to lower the oxidative injury in the retina.
Similarly, Cui et al. in 2017 [177] explored whether bone mesenchymal stem cells (BMSCs)
could prevent hydrogen peroxide-induced damage in retinal ganglion cells, by using immortalized
retinal ganglion cells, RGC-5 cells. Exposure to BMSCs actively avoided retinal cell death, reducing
H2O2-induced inflammatory factors IL-1β and TNF-α, downregulating intracellular oxidant factor
malondialdehyde (MDA), and upregulating the intracellular antioxidant enzyme SOD and the
expression of the neurotrophins CNTF and BDNF. Thus, BMSCs may induce defensive effect in
RGC-5 cells against H2O2-induced injury enhancing the antioxidant potential, promoting neurotrophin
expression and decreasing pro-inflammatory cytokine secretion.
It has been suggested that the method to obtain the best secretome for diabetic neuropathy (DN)
treatment is by preconditioning MSCs that triggers an increase of the total antioxidant ability of the
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secretome. Oses et al. [178] demonstrated that the preconditioning of human AD-MSCs, with the iron
chelator deferoxamine (DFX), increased the expression of the hypoxia inducible factor 1 alpha (HIF-1α),
without effects on MSC morphology and survival. This was accompanied by an increased release of
potent neuroprotective factors, such as nerve growth factor, glial cell-derived neurotrophic factor and
neurotrophin-3, and cytokines with anti-inflammatory activity, such as IL-4 and IL-5. Moreover, DFX
displayed neuroprotective effects also in an in vitro model of DN. Altogether, this study demonstrates
that preconditioning with DFX improves therapeutic potential of AD-MSCs, suggesting this approach
as a good strategy for DN treatment. As previously underlined, ALS is characterized by death of
lower and upper motoneurons. Bonafede et al. [179] isolated exosomes from murine adipose-derived
stromal cells and tested their efficacy on motoneuron-like NSC-34 cells expressing ALS mutations,
as in vitro model of this disease. Exosomes demonstrated the ability to protect NSC-34 cells from
oxidative damage, which is one of the central mechanisms of damage in ALS, and thus to increase
cell viability. Maguire et al. [180] used the secretome obtained from four cell types, namely MSCs,
fibroblast, neural stem cells, and astrocytes, demonstrating a slowdown in neuron and neural cell
degeneration. In particular, sodium arsenite-induced oxidative stress in a human recombinant TDP-43
or FUS-tGFP U2OS cell line was used as in vitro model of ALS and frontotemporal dementia. This was
significantly reduced by the exposure to the molecules released by MSCs. Furthermore, they also
showed that the whole MSC secretome saves cortical neurons from glutamate toxicity, as demonstrated
by better neurite outgrowth, reducing both LDH release and caspase 3/7 activity. On these bases, stem
cells exosomes can also be a promising strategy in therapeutic applications for motoneuron diseases.
Friedreich’s ataxia (FA) cells are particularly vulnerable to oxidative stress. Jones et al. [181] exposed
FA-cells to oxidative stress in the presence of adipose stem cell-conditioned medium. Interestingly,
AD-MSC-CM enhanced cell survival and upregulated oxidative-stress-associated genes such as frataxin,
among other genes. Moreover, this work showed that neurotrophic factors, particularly BDNF, play a
central role in enhancing cell survival contrasting oxidative stress.
Taking all together, the exposure to MSCs or their secretome can be considered as a promising
therapeutic strategy to enhance antioxidant capacity and neurotrophin expression while inhibiting
pro-inflammatory cytokine secretion, that are common aspects of neurodegenerative pathologies.
Table 1. Neurogenic differentiation protocols.
Compounds Neuronal Markers Types of Neuronal Cells Types of MSC Ref.
10% AP-g-CH/GL/AG
scaffold + RA, Shh, BDNF,
GDNF
Hb-9
Islet-1
ChAT
TCP
Motor neuron-like cells hOE-MSCs [182]
Shh, bFGF, FGF8 and
BDNF in free-serum
condition
TUJ1 (28–60% of cells)
TH
NSE
EN1
GLI1
NURR1
VMAT2
GIRK2
Dopaminergic neurons hADSCs [183]
PVA/SA nanofibers + beta
carotene
Morphology
MAP-2 Neural-like cells hBMSCs [184]
PEMF
Morphology (elongated spindle shape)
CD104
S100
GFAP
laminin
P75NTR
Schwann-like cells hDPSCs [185]
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Table 1. Cont.
Compounds Neuronal Markers Types of Neuronal Cells Types of MSC Ref.
Lamin and PDGF-BB
Nestin
MAP2
β-tubulin III
Nerofilament-M
Neuron-like cells hUSCs [186]
Phase I: trans-RA
Phase II: N2B27
GAPDH
Nestin
Sox1
β-tubulin III
NF200
Phase I: NPCs
Phase II: mature cells of
the neural lineage
MESC lines: A2lox
and 129 [187]
Serum-free + BDNF +
NT-3/neurotrophins
β-tubulin III
Nestin
Connexin (Cx26, Cx43)
Pannexin (Pnx1)
NTRK2, NTRK3
NGF, BDNF, NT-3 expression
Central NSC and
peripheral neural crest
stem cells
hDPSCs [188]
10% FBS, Retinoic acid GFAP, β-III tubulin, CNPase, MAP2, NeuN,synapsines, S100, PMP22
Neuron-like cells,
oligodendrocyte-like cells hAFSC [189]
Heparin mix with FGF
ChAT genes expression
β-tubulin III
MAP2
Sox1
Dopaminergic neurons hADSCs [190]
Retinoic acid mix with
EGF, FGF2, BMP-9
TH genes expression
β-tubulin III
MAP2
Cholinergic neurons hADSCs [190]
BME + NGF
NF-68, NF-160, NF-200
NeuroD
ChAT
MAP-2
synapsin-1
Choliergic neurons mBMSCs [191]
Melatonine
β-tubulin III
TH
NURR1
GFAPdecrease
CD29, CD45, CD73, CD90, CD105decrease
DAT
Dopaminergic neurons hAF-MSCs [192]
SHH + RA
Neuron-like morphology
NF-M
TuJ-1
vimentin
synapsin
membrane potential (−70/−65 mV)
Cholinergic neurons Monkey BMSCs [193]
Cyclic ketamine
Filamin-B
Rac1
thioredoxine
peroxiredoxin-1
Gelsolin
Galectin-3
Neurons hADSC [194]
BDNF + FGF2
MAP2
TH
NGN2
PITX3
DAT
synaptophysin
Kv4.2
SCN5A
Dopaminergic neurons hDPSCs [195]
TMP
Neuronal morphology
MAP-2
NSE
Ngn1
NeuroD
Mash1
Neurons mBMSCs [196]
e-CSF β-tubulin IIIneurite outgrowth assay Neuronal-like cells m-ADSCs [197]
AP-g-CH/GL/AG scaffold, chitosan-graft-aniline pentamer, gelatin, agarose; hOE-MSCs, human olfactory
ecto-mesenchymal stem cells; hADSC, human adipose tissue-derived stem cells; NSE, neuron specific enolase; EN1,
engriled homebox 1; GLI1, GLI family zinc finger 1; NURR1, nuclear receptor-related factor 1; VMAT2, vesicular
monoaminetransporter 2; GIRK2, G-protein-regulated inward-rectifier potassium channel 2; PVA/SA, polyvinyl
alcohol/sulphated alginate; hBMSCs, human bone marrow stem cells; PEMF, used electromagnetic field; hDPSCs,
human dental pulp stem cells; PDGF-BB, platelet-derived growth factor BB; hUSCs, human urine-derived stem
cells; RA, retinoic acid; mESC, mouse embryonic stem cell; NPCs, neural precursor cells; mBMSCs, murine bone
marrow stem cells; BME, β-mercaptoethanol; NGF, nerve growth factor; ChAT, choline acetyl transferase; DAT,
dopamine transporter; TMP, tetramethylpyrazine; MAP-2, microtubule-associated protein 2; NSE, neuron-specific
enolase; Ngn1, neurogenin 1; NeuroD, neuronal differentiation 1; Mash1, mammalian achaete-scute homolog 1;
e-CSF, embryonic cerebrospinal fluid.
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Table 2. MSC studies on in vitro models of neurodegenerative diseases.
In Vitro Model Analyzed Pathways MSC Sources Redox Pathway Involved Ref.
Primary hippocampal
cultures exposed to Aβ
TUNEL staining
DHE staining hUCB-MSCs co-culture
Reduction of oxidative stress and
apoptosis level [168]
(LPS)-activated microglial
cells
AMPK pathway
TNF-α, IL-1β, IL-6, PEG2,
NADPH oxidase activity,
ROS, MDA, SOD, GSH-Px
hBM-MSCs co-culture
Inhibitory effect on the
pro-inflammatory mediators and
oxidative stress by AMPK pathway
[166]
Neuroectodermal lineage
cells treated with H2O2
NeuroD and Nestin expression,
Bax,
Bcl-2
OAMSCs-CM containing
neurotrophic factors
Abrogation of neuronal cell damage
induced by oxidative stress [162]
RGC-5 cells (diabetic
retinopathy (DR))
Cell viability
IL-1β and TNF-α
MDA and antioxidant enzymes (such as SOD)
BDNF
CNTF
mBMSCs co-culture
Reduction of H2O2-induced
inflammatory factor,
downregulation of intracellular
oxidant factor (MDA) and
upregulation of intracellular
antioxidant factor (SOD),
increase of neurotrophins
expression
[177]
6-OHDA-induced PD cell
model Cell viability
hCVC-CM (nestin,
connexin 43, VEGF)
Reduction of neurotoxin-induced
apoptosis,
enhancement of cell-recovery
following neuronal damage
[174]
NSC-34 cells expressing
ALS mutation (in vitro
model of ALS)
H2O2-induced cytotoxicity mADSC-exo
Neuroprotective effect of low
concentration of exosomes on cell
viability and protection from
oxidative damage
[179]
FA cells model
(periodontal ligament
cells from FA patient)
CD44, CD34, CD-90
cleaved caspase-3
Oxidative-stress-related genes (such as frataxin)
BDNF
hADSC-CM
Change of transcription levels of
oxidative-stress-related genes
avoiding cellular degeneration
[181]
SH-SY5Y (MPP+ for
inducing PD)
Cell viability
pro-inflammatory cytokines,
mitochondrial membrane potential (∆ψm)
oxidative stress (DHE assay)
cell apoptosis
hMenSC-CM
Increase of cell viability, reduction
of MPP+ induced inflammation,
∆ψm loss, ROS generation and cells
numbers in late apoptosis stage
[175]
SH-SY5Y (PD)
ROS detection (DCFDA)
SOD2
Hsp70
SIRT1
SIRT3
RAA-MSC-CM
Reduction of mortality and ROS
generation
Upregulation of the antioxidant
enzyme SIRT3
(SIRT1 and Hsp70 unchanged)
[173]
SH-SY5Yd exposed to
H2O2
Cell viability assay
ROS detection (DCFDA)
Morphological analysis
ASC-CM
Moderate reduction of ROS and
maintenance of an appropriate
redox state to preserve
neuronal function
[164]
Rat organotypic
hippocampal cultures
GFAP
Microglial cells detection (isolectin-B4)
TNF-α, IL-6
ROS measurement (DCF-DA)
iNOS
rBMSC-CM
Induction of glial activation
Increase of ROS generation and
neuroinflammation
[165]
Primary rat hippocampal
cultures exposed to AβOs
ROS measurement (DCF-DA)
Catalase detection hMSC-EVs
Protection from oxidative stress and
synapse damage induced by AβOs
Reduction (via catalase activity) of
abnormal ROS production and
propagation of astrocyte neurotoxic
effects induced by AβOs
[170]
Human recombinant
TDP-43-tGFP U2OS cell
line exposed to sodium
arsenite
FUS
TDP-43
Cell viability
caspase-3
LDH release
hADSC-CM
Inhibition of stress granule number
Rescue from glutamate toxicity,
reduction of LDH release and
caspase 3/7 activity
[180]
T98G cells (human
astrocytes) subjected to
scratch injury
IL-2, IL-6, IL-8, IL-10, TNF-α
ROS determination (DHE)
membrane potential (∆ψm)
Ca2+ intracellular
GM-CSF
AKT/pAKT
ERK1/ERK2/pERK
Ngb localization
hMSAC-CM
Modulation of localization and
expression of neuroglobin
Protective effects through regulation
of proteins involved in survival
pathways and oxidative stress
[161]
Rat DGR neurons
HIF-1α, NGF, neuroptophin-3, glial cell-derived
neurotrophic factor, IL-4, IL-5, VEGF,
angiopoietin 1
hAD-MSC secretome
DFX (iron chelator deferoxamine)
preconditioning significantly
increased the total antioxidant
capacity of the MSC secretome
[178]
hUCB-MSCs, human umbilical cord blood-derived mesenchymal stem cells; hBM-MSCs, human bone
marrow-derived mesenchymal stem cells; hOAMSCs, human orbital adipose tissue-derived mesenchymal stem
cells; mBMSCs, murine bone marrow stem cells; 6-OHDA, 6-oxidopamine; hCVC, human chorionic villi cells; ALS,
amyotrophic lateral sclerosis; mADSC, murine adipose-derived stem cell; FA, Friedreich’s ataxia; hADSC, human
adipose-derived stem cell; MPP, 1-methyl-4-phenylpyridinium; DCFDA, 2′-7′dichlorofluorescin diacetate; hMenSC,
human menstrual blood-derived endometrial stem cell; RAA-MSC, rat adipose tissue-derived MSC; rBMSC, rat
bone marrow stem cells.
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Table 3. MSC studies on in viivo models of neurodegenerative diseases.
In Vivo Model Analyzed Pathways MSC Sources Redox Pathway Involved Ref.
Diabetic retinopathy
mouse model
NGF
bFGF
GDNF
AD-MSC injection (robust
expression of SOD1,
SOD2, CAT, GPX1)
Reduction of oxidative damage:
small reduction in the ROS level but
strong reduction in lipid
peroxidation levels
[176]
PD mouse model
(C57BL/6J MPTP-PD
induced model)
Behavioral assessment (Wire Hang and Rotarod)
GFAP and BLBP-expression
Iba-1
NPs injection obtained
from ESCs and MSCs
Amelioration of the motor
symptoms
Significantly reduction of reactive
astroglia and microglia cells
Reduction of astroglia and
macrophages
[172]
AD model mice (APdE9)
MWM test
Aβ deposition
Iba-1
CD14-positive microglia
Aβ1-40 and Aβ1-42 ELISA assay
EPR imaging system
MSC injection (tail vein)
Amelioration of oxidative stress
through upregulation of microglia
expression
Promotion of microglial Aβ uptake
and clearance
Decrease of Aβ-dependent ROS
production, thereby improving the
redox balance
[171]
AβPP/PS1 mouse model
of AD
Reduction of β-secretase 1 and CTFβ, and Aβ
deposition hUCB-MSCs vain infusion
Increased GSH and SOD activity.
Decreased malondialdehyde
activity and protein carbonyl level
[169]
C57BL/6J mice (acute
Aβ-induced AD model)
MWM test
DHE staining
TUNEL staining
GFAP staining
Iba-1 staining
hUCB-MSCs transplant
Recover of impaired memory
function
Inhibition of oxidative stress and of
glial activation that mediates
apoptosis
[168]
hADSC, human adipose-derived stem cell; NPs, neuronal precursors; ESCs, embryonic stem cells; MSCs,
mesenchymal stem cells; hUCB-MSCs, human umbilical cord blood-derived mesenchymal stem cells; GSH,
glutathione; SOD, superoxide dismutase.
4. Conclusions
Neurodegenerative diseases represent a group of disorders characterized by a slow and chronic
loss of different neuronal populations in the CNS. All of them possess a complex and multifactorial
etiology and share common characteristic among which oxidative stress plays a fundamental role.
In view of the complex multifactorial nature of neurodegenerative diseases, interventions
concurrently targeting different risk factors and disease mechanisms at an early stage of the diseases are
most likely to be successful. For this purpose, the contribution of stem cells has been widely explored
over the past years and neuro-restoration seems to be a promising strategy (Figure 4).
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In particular the exposure to mesenchymal stem cells can be considered as a promising therapeutic
tool for neurodegenerative diseases since MSCs:
- enhance antioxidant capacity;
- increase neurotrophin expression;
- inhibit pro-inflammatory cytokine secretion; and
- counteract microglial ROS production.
The main criticism is that the clinical application of stem cell therapy in counteracting
neurodegeneration in humans is still questionable, generating both interests and alarms in the
scientific community. The most interesting approach to overcome these criticisms could be to avoid
cells injection employing only the secretome, namely extracellular vesicles, obtained from MSCs
cultured in vitro and properly preconditioned in order to reach the best pool of bioactive molecules.
In this sense, since EVs are apparently well-tolerated, their use paves the way for innovative and more
efficient therapies based in nanomedicine, avoiding the putative side effects associated with stem cell
transplantation. However, differences in MSCs and secretome can occur, depending on the tissue
source, and characteristics of the donor, such as age.
Therefore, further studies are needed to identify a tailored approach for each neurodegenerative
disease in order to design more effective therapeutic stem cell strategies to prevent a broad range of
neurodegenerative disorders. Indeed, in the future, it will be necessary to challenge several, and still
unsolved, problems such as: (1) the appropriate number of stem cells or exosomes to transplant; (2) the
optimal timing of transplantation; (3) the correct disease stage for cell transplantation; and (4) the
evaluation of the therapeutic effectiveness of the different kind of MSCs in terms of safety, function
recovery, and motor and cognitive improvement.
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AGEs advanced glycation end products
ALS amyotrophic lateral sclerosis
APP amyloid-protein precursor
ARE antioxidant response element
ASCs adult stem cells
BDNF brain-derived neurotrophic factor
BME β-mercaptoethanol
BM-MSCs bone marrow-derived mesenchymal stem cells
CM conditioned medium
CNS central nervous system
CVC chorionic villi cells
DA dopamine
DAT DA transporter
DCFH-DA 2′-7′dichlorofluorescin diacetate
DPSC dental pulp stem cells
e-CSF embryonic cerebrospinal fluid
ESCs embryonic stem cells
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FA Friedreich’s ataxia
FSCs fetal stem cells
GSH glutathione
HD Huntington’s disease
HIF-1α hypoxia inducible factor 1 alpha
iPSCs induced pluripotent stem cells
MAP-2 microtubule-associated protein 2
MDA malondialdehyde
MenSC menstrual blood-derived endometrial stem cell
MSCs mesenchymal stem cells
NeuroD neuronal differentiation 1
NFTs neurofibrillary tangles
NGF nerve growth factor
Ngn1 neurogenin 1
NO nitric oxide
NOS nitric oxide synthase
NOXs NADPH oxidases
NPCs neural precursor cells
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Nrf2 nuclear factor erythroid 2-related factor 2
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